An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma-Reference-Cited by-同舟云学术

An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma

Published:2018-02-15 Issue:7 Volume:131 Page:746-758
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lee Lydia¹^ORCID,Draper Benjamin¹,Chaplin Neil¹,Philip Brian¹,Chin Melody¹,Galas-Filipowicz Daria¹,Onuoha Shimobi²,Thomas Simon²,Baldan Vania²,Bughda Reyisa²,Maciocia Paul¹,Kokalaki Eva¹,Neves Margarida P.¹,Patel Dominic³,Rodriguez-Justo Manuel³,Francis James²,Yong Kwee¹,Pule Martin¹²

Affiliation:

1. Department of Haematology, University College London (UCL) Cancer Institute, London, United Kingdom;

2. Autolus Ltd., London, United Kingdom; and

3. Department of Histopathology, UCL, London, United Kingdom

Abstract

Key Points APRIL is a compact, self-protein that binds 2 MM antigens (BCMA and TACI) with high affinity; we present an APRIL-based CAR. Dual-antigen targeting increases the availability of tumor-binding sites and reduces the risk of antigen-negative disease escape.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/7/746/1406971/blood781351.pdf

Reference68 articles.

1. Mortality data;National Center for Health Statistics, Centers for Disease Control and Prevention

2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

3. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

4. CAR therapy: the CD19 paradigm;Sadelain;J Clin Invest,2015

5. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N Engl J Med,2013

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates on CAR T cell therapy in multiple myeloma;Biomarker Research;2024-09-12

2. Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CARNK cells;Molecular Therapy - Methods & Clinical Development;2024-09

3. Effectors of the Future: Universal Chimeric Antigen Receptor;Transfusion Medicine and Hemotherapy;2024-07-15

4. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model;Blood;2024-07-11

5. Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial;The Lancet Haematology;2024-07